Nanexa

PharmaShell has been developed to create long-acting injectable formulations with tailored depot duration and controlled release.

PharmaShell is Nanexa’s proprietary and patented drug delivery platform for long-acting injectable medicines.

Nanexa’s NEX-20, a treatment for multiple myeloma, is currently on hold.

NEX-22 Monthly and Quarterly GPL-1 Analogues for Treatment of Type 2 Diabetes and ObesityControlled release for fewer injections.

Göran Ando proposed as new Chairman of the Board of Nanexa AB (publ)

Uppsala 6th Sep 2017 Important results from animal studies with PharmaShell as parenteral depot preparation During the current quarter,Read more

Nanexa launched a self-owned oncology product project following a share issue decision by its board.

Uppsala 9th Oct 2017 Nanexa investigates PharmaShell in a new animal study Based on the good results from the PharmaShell animal study conducted during the third quarter of 2017,Read more

Uppsala 29th July 2017 Nanexa upscales the PharmaShell process During the spring, Nanexa has scaled up the PharmaShell process and can now produce ten times more material than in previous lab scale.Read more

Nanexa seeks a Project Manager to collaborate with its Director of Project Management and drive drug development projects from preclinical to clinical stages.

The auditor shall review the company’s annual report and the accounts, as well as the administration of the board and the CEO. After each financial year, the auditor shall submit an audit report to the AGM.Read more

Nanexa’s business model is based on developing the company’s drug delivery platform PharmaShell, as well as running product projects based on the company technology. Nanexa aims at out-licensing the right to use the technology in specified areas.Read more

Nanexa is a drug development company creating long-acting injectable medicines with the potential to make treatment more convenient.

Nanexa AB is a Swedish public limited company, whose shares have been traded on Nasdaq First North Growth Market since 29 May 2020, and prior to that on Spotlight Stockmarket,Read more

Atomic Layer Deposition (ALD) provides precise, conformal nanoscale film coatings for advanced electronics and semiconductor products.

Nanexa AB Adress Virdings Allé 2 SE-75450 Uppsala, Sweden Phone +46 (0) 18 100 300 Org nr 556833-0285 E-mail info@nanexa.se David Westberg,Read more

Redefining Injectables.One Layer at a Time. Company presentationRead more

Nanexa AB’s stock surges 105% after securing a drug-delivery licensing agreement with Novo Nordisk. The deal, announced on September 24, could yield up to €1.165 billion in payments, including upfront, development, and regulatory milestones. The partnership leverages Nanexa’s technology for potential pharmaceutical applications.

Sep 2026MuggleheadNews article

Nanexa grants Novo an exclusive global license for its PharmaShell® atomic layer deposition (ALD) technology platform. The deal targets long-acting injectable peptide drugs for obesity, type 2 diabetes, and cardiometabolic diseases. The collaboration includes a EUR 1.165 billion agreement.

Sep 2026Yahoo FinanceNews article

Novo secures an exclusive global license for Nanexa’s PharmaShell® atomic layer deposition (ALD) technology, targeting long-acting peptide drugs in obesity, type 2 diabetes, and cardiometabolic diseases. The collaboration includes a EUR 1.165 billion agreement, granting Novo rights to integrate Nanexa’s proprietary drug delivery platform into its therapeutic pipeline. The partnership focuses on advancing next-generation injectable treatments for metabolic conditions.

Sep 2026MarketScreenerNews article

Nanexa licenses its PharmaShell platform to Moderna to develop long-acting injectable versions of Moderna’s mRNA therapies. The collaboration aims to extend the duration of Moderna’s existing mRNA-based treatments. Nanexa provides drug delivery technology to enhance formulation stability and dosing frequency.

Dec 2025The Pharma NavigatorNews article